Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Interim REFRESH results demonstrating that among 67 patients (approximately half oxybate naïve, 37% switches from twice-nightly oxybates, and the remainder previous twice-nightly oxybate users); ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

If your portfolio includes an index fund, you may need to review and adjust your holdings. Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.